Screener
Kymera Therapeutics KYMR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 1,251 | 1,362 |
| Operating lease liabilities | (2,834) | (2,416) |
| Other assets and liabilities | (4) | (106) |
| Net cash used in operating activities | $(142,905) | $(139,034) |
| Investing activities | ||
| Purchase of property and equipment, net | (907) | (1,162) |
| Purchases of investments | (390,921) | (141,907) |
| Maturities of investments | 269,033 | 251,705 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's operating cash flow?
- Kymera Therapeutics (KYMR) reported operating cash flow of -$54.07M in Q2 2026.
- How has Kymera Therapeutics's operating cash flow changed year-over-year?
- Kymera Therapeutics's operating cash flow increased by 9.7% year-over-year, from -$59.88M to -$54.07M.
- What is the long-term trend for Kymera Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's operating cash flow has grown at a 15.9% compound annual growth rate (CAGR), from -$128.95M to -$232.89M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Kymera Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude